Angiogenesis Inhibition

ISBN-13: 9783642261435 / Angielski / Miękka / 2012 / 231 str.

R. Diger Liersch; Wolfgang E. Berdel; Torsten Kessler

Opis

Angiogenesis is attracting increased scientific and clinical interest. The identification of novel mediators and targeting molecules has led to significant progress in our understanding of tumor angiogenesis and tumor vessel targeting. Important advances in cancer treatment have already emerged, and in the future, blood vessel targeting will play a significant role within individualized therapeutic strategies. This volume provides a general overview of the latest developments in angiogenesis inhibition in cancer. All aspects from the bench to the bedside are considered, with detailed attention both to basic research and to its translation into clinical practice. Individual chapters are devoted to the roles of angiopoietins, HIF-1a, chemokines, PDGF and VEGF, and vascular integrins. The latest results of clinical trials are presented, and various advanced targeting strategies are discussed. This book will be invaluable to all who wish to learn of the most recent advances in this exciting field.

Spis treści

Angiopoietins.- HIF-1? and Cancer Therapy.- Chemokines.- Angiogenesis Inhibition in Cancer Therapy.- Vascular Integrins: Therapeutic and Imaging Targets of Tumor Angiogenesis.- PDGF and Vessel Maturation.- Lymphangiogenesis in Cancer: Current Perspectives.- Compounds in Clinical Phase III and Beyond.- Metronomic Chemotherapy: Principles and Lessons Learned from Applications in the Treatment of Metastatic Prostate Cancer.- Targeting Inflammatory Cells to Improve Anti-VEGF Therapies in Oncology.- Antibody-Based Vascular Tumor Targeting.- Caveolae and Cancer.

O autorze

Torsten Kessler ist Mitarbeiter der SAP Deutschland AG & Co. KG und seit 2006 als Berater im Bereich Business Intelligence/SAP NetWeaver BW tätig. In den ersten Jahren der SAP-Beratung lag sein Fokus auf dem Reporting und der Analyse. Seine Aufgaben waren die konzeptionelle Ausarbeitung und Implementierung von Dashboards und portalbasierten Analyselösungen. Später hat Torsten Kessler seinen Schwerpunkt in den Backendbereich von BW verlagert. Heute ist er vor allem für die Konzeption und Entwicklung von LSA-Architekturen und EDW-Konzepten verantwortlich. Torsten Kessler verfügt über große Erfahrung im EDI-Bereich, was ihn besonders für den Bereich der Fremdsystemanbindung qualifiziert. Innerhalb von EDW-Projekten ist er deshalb Expterte für die Datenbeschaffung und die Datenbereitstellung. Neben seiner Beratungstätigkeit ist Herr Kessler für die Weiter-entwicklung und Durchführung des SAP-Kurses BW Backend und Programmierung von SAP Education verantwortlich.

Blurb

Angiogenesis is attracting increased scientific and clinical interest. The identification of novel mediators and targeting molecules has led to significant progress in our understanding of tumor angiogenesis and tumor vessel targeting. Important advances in cancer treatment have already emerged, and in the future, blood vessel targeting will play a significant role within individualized therapeutic strategies.

This volume provides a general overview of the latest developments in angiogenesis inhibition in cancer. All aspects from the bench to the bedside are considered, with detailed attention both to basic research and to its translation into clinical practice. Individual chapters are devoted to the roles of angiopoietins, HIF-1a, chemokines, PDGF and VEGF, and vascular integrins. The latest results of clinical trials on therapeutic compounds are presented, and various advanced targeting strategies are discussed. This book will be invaluable to all who wish to learn of the most recent advances in research and treatment in this exciting field.